Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of AD-109 (rivaroxaban 18mg) vs AD-1091 (rivaroxaban 20mg) in healthy males
NCT05128591Phase 1Completed
- Sponsor
- Addpharma, Inc.
- Start
- Nov 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of rivaroxaban in embolism and thrombosis (2 arms), sponsored by Addpharma, Inc. Primary endpoints: Peak Plasma Concentration and Area Under the Curve. Started Nov 2021; status: completed.
02
Drugs
rivaroxaban
03
Conditions
embolism and thrombosis
Beyond the preview
Go deeper on NCT05128591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05128591.